Research Analysts Issue Forecasts for FDMT FY2030 Earnings

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) – Investment analysts at HC Wainwright issued their FY2030 earnings estimates for shares of 4D Molecular Therapeutics in a research note issued on Friday, March 20th. HC Wainwright analyst M. Caufield forecasts that the company will earn ($2.61) per share for the year. HC Wainwright currently has a “Buy” rating and a $36.00 target price on the stock. The consensus estimate for 4D Molecular Therapeutics’ current full-year earnings is ($2.84) per share.

Several other research analysts have also commented on FDMT. Wall Street Zen raised 4D Molecular Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, January 21st. Barclays started coverage on 4D Molecular Therapeutics in a research note on Wednesday, January 28th. They issued an “overweight” rating and a $33.00 target price on the stock. Chardan Capital reiterated a “buy” rating and issued a $26.00 target price on shares of 4D Molecular Therapeutics in a report on Thursday. Finally, Royal Bank Of Canada increased their price target on shares of 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an “outperform” rating in a research report on Thursday. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $32.71.

4D Molecular Therapeutics Stock Down 4.1%

4D Molecular Therapeutics stock opened at $8.61 on Monday. The firm has a market cap of $439.54 million, a P/E ratio of -3.56 and a beta of 2.99. The business has a fifty day moving average of $8.75 and a two-hundred day moving average of $9.14. 4D Molecular Therapeutics has a twelve month low of $2.23 and a twelve month high of $12.34.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings data on Wednesday, March 18th. The company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.96. The company had revenue of $85.09 million for the quarter, compared to analyst estimates of $30.86 million. 4D Molecular Therapeutics had a negative net margin of 164.43% and a negative return on equity of 31.75%.

Institutional Trading of 4D Molecular Therapeutics

A number of institutional investors have recently made changes to their positions in FDMT. Dynamic Technology Lab Private Ltd purchased a new position in 4D Molecular Therapeutics during the 1st quarter worth $39,000. Wexford Capital LP acquired a new position in 4D Molecular Therapeutics during the 3rd quarter valued at about $41,000. Quadrature Capital Ltd purchased a new stake in 4D Molecular Therapeutics in the second quarter valued at about $42,000. Farther Finance Advisors LLC raised its stake in 4D Molecular Therapeutics by 117.4% in the third quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock valued at $43,000 after buying an additional 2,674 shares during the last quarter. Finally, AQR Capital Management LLC acquired a new stake in 4D Molecular Therapeutics in the first quarter worth about $46,000. Institutional investors and hedge funds own 99.27% of the company’s stock.

Key Stories Impacting 4D Molecular Therapeutics

Here are the key news stories impacting 4D Molecular Therapeutics this week:

• Positive Sentiment: High-profile firms reiterated bullish views and raised targets, supporting upside potential — HC Wainwright reaffirmed a “buy” and set a $36 target (very large implied upside). Read More.
• Positive Sentiment: Royal Bank of Canada raised its price target to $35 and gave an “outperform” rating, signaling strong analyst conviction on mid/long-term value. Read More.
• Positive Sentiment: Chardan Capital reaffirmed a “buy” with a $26 target, adding another supportive research note. Read More.
• Positive Sentiment: Fundamental beat: 4D reported Q4 EPS of $0.43 (well ahead of consensus) and revenue of $85.1M, which typically supports higher valuations and reduces near-term execution risk. Read More.
• Neutral Sentiment: Analyst commentary is mixed across the sector; some aggregation pieces note divergent views on FDMT which can increase intraday volatility without clear directional pressure. Read More.
• Neutral Sentiment: Short-interest reports in the latest feeds show anomalous/zero values (reports indicate increases but list 0 shares/NaN), suggesting the data feed is unreliable — this appears to be noise rather than a clear short-squeeze or large shorting event.
• Negative Sentiment: Cantor Fitzgerald issued a “hold” on FDMT, which can dampen momentum from the bullish notes and makes the street’s view less one-sided. Read More.
• Negative Sentiment: New risk disclosure: a TipRanks piece highlights reimbursement and pricing pressures that could materially affect the commercial outlook for FDMT’s gene therapies — a real demand/price-risk that can weigh on valuation and near-term sentiment. Read More.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.